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Abstract
Background: Toxocariasis is a neglected parasitic zoonosis that afflicts millions of the pediatric and adolescent
populations worldwide, especially in impoverished communities. This disease is caused by infection with the larvae
of Toxocara canis and T. cati, the most ubiquitous intestinal nematode parasite in dogs and cats, respectively. In this
article, recent advances in the epidemiology, clinical presentation, diagnosis and pharmacotherapies that have been
used in the treatment of toxocariasis are reviewed.
Main text: Over the past two decades, we have come far in our understanding of the biology and epidemiology of
toxocariasis. However, lack of laboratory infrastructure in some countries, lack of uniform case definitions and
limited surveillance infrastructure are some of the challenges that hindered the estimation of global disease burden.
Toxocariasis encompasses four clinical forms: visceral, ocular, covert and neural. Incorrect or misdiagnosis of any of
these disabling conditions can result in severe health consequences and considerable medical care spending.
Fortunately, multiple diagnostic modalities are available, which if effectively used together with the administration
of appropriate pharmacologic therapies, can minimize any unnecessary patient morbidity.
Conclusions: Although progress has been made in the management of toxocariasis patients, there remains much
work to be done. Implementation of new technologies and better understanding of the pathogenesis of
toxocariasis can identify new diagnostic biomarkers, which may help in increasing diagnostic accuracy. Also, further
clinical research breakthroughs are needed to develop better ways to effectively control and prevent this serious
disease.
Keywords: Toxocara canis, Toxocariasis, Zoonosis, Larva migrans, Epidemiology, Diagnosis, Control
Multilingual abstracts
Please see Additional file 1 for translations of the
abstract into five official working languages of the
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Background
Toxocariasis is a prevalent zoonosis with a significant
socioeconomic impact, particularly on impoverished
communities around the world. It is caused by nematode
parasites of the genus Toxocara, of which dog
roundworm (Toxocara canis; Werner, 1782) and to a
lesser extent, cat roundworm (Toxocara cati; Schrank,
1788) cause severe disease in humans [1]. In the natural
definitive hosts – dogs and cats – these parasitic round-
worms colonize the intestinal tract and excrete Toxocara
eggs with faeces into the environment [2]. The round-
worm Toxocara is a perfect example of a parasite mov-
ing from wild canids to their domestic counterparts and
to humans [3, 4]. Dogs or cats, especially in low-income
and rural regions, play important roles in the transmis-
sion of Toxocara spp. through environmental contamin-
ation, which spreads the infection to humans [3].
Humans are considered as an accidental or aberrant
host, therefore, Toxocara larvae cannot develop into
adult worms inside the human body [2, 4–6].
Humans acquire infection via ingestion of embryo-
nated/larvated eggs present in the soil or contaminated
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food, or by ingestion of encapsulated Toxocara larvae in
improperly cooked tissues of paratenic hosts, such as
cows, sheep and chickens [2, 4–9]. Following ingestion
of embryonated eggs, larvae hatch in the small intestine,
penetrate the intestinal wall, gain access to circulation,
migrate throughout the body, leading to a marked in-
flammatory response and various clinical symptoms,
depending on the organ involved [1, 7, 9, 10]. Although
infection in humans can be asymptomatic, Toxocara
parasite has a notorious tendency to cause extra-
intestinal pathologies [7, 8]. Indeed, toxocariasis includes
four clinical forms, which can lead to serious health con-
sequences [7, 9, 10]. Due to the non-specific symptoms
of this disease, its medical and public health impact
might be underestimated [11, 12]. Thus, although toxo-
cariasis can be diagnosed tentatively based on patient’s
symptoms, laboratory diagnosis is required to improve
the accuracy of diagnosis [13, 14].
The first human infection was reported in 1950 [15],
and since then it has been reported in almost 100 coun-
tries [7, 8]. Over the last few years, toxocariasis has
gained an increasing international attention and was
listed among the five most neglected parasitic infections
according to the US Centers for Disease Control and
Prevention (CDC) [3, 4, 12, 16]. The newly sequenced
genome of T. canis along with transcriptomic analysis
has allowed an in-depth characterization of this organ-
ism’s molecular characteristics [18]. Also, knowledge of
the parasite’s genetic diversity has been improved and
new diagnostic markers have been discovered [9, 18–20].
These achievements reflect the increased awareness of
toxocariasis and recognition of its continued public
health impact. In this article, we provide an updated
review of data on toxocariasis, with a focus on the
epidemiological, diagnostic and therapeutic aspects of
the disease.
Review
The causative agents
Toxocara spp. are classified under the super-family
Ascaridoidea [21–23], and include four valid species,
namely Toxocara canis, T. cati, T. malaysiensis, and T.
vitulorum [21, 22]. Phylogenetic analyses based on the
ITS-2 and 28S sequences of the nuclear ribosomal DNA
(rDNA), showed that Toxocara spp. form a distinct
clade, in relation to their definitive hosts, which is separ-
ate from Ascaris spp. [24]. Moreover, phylogenetic
analysis of T. vitulorum, T. canis, T. cati, T. malaysiensis,
Ascaris suum, Anisakis simplex, and Onchocerca volvu-
lus based on amino acid sequences of the entire mito-
chondrial (mt) genome, revealed that Toxocara spp. are
more closely related to A. suum than to A. simplex and
O. volvulus; and that T. malaysiensis is more closely
related to T. cati than to T. canis [19]. T. vitulorum has
been shown, based on partial mt genome sequence, to be
more closely related to T. malaysiensis than to T. canis
and T. cati [25]. T. vitulorum, T. canis and T. cati, have
been reported worldwide, however T. malaysiensis was
only reported in China, Malaysia, and Vietnam [26–29].
Neither nucleotide variation of ITS-1 and ITS-2 in T.
canis from different hosts, including dogs, foxes, and
turkey, was observed; nor was there significant intra-
specific variability (with none exceeding 0.4%) between
specimens from Japan, England, Australia, Sri Lanka and
Poland [30]. In regard to T. cati, no variation in IT-S
sequences within one host was detected, but rDNA
microheterogeneity within specimens originating from
different geographical locations was reported [28, 31].
Polymorphism analysis of T. cati from different geo-
graphical locations has shown that differences between
Malaysian and Australian strains are 2.9% for ITS-1 and
0.3% for ITS-2 [31], and the ITS sequences of T. cati
from Poland and Australia differed slightly (0.3–0.4%).
However, the differences were much more significant for
T. cati from Malaysia (2% in ITS-1 and 0.6% in ITS-2)
[30]. Interestingly, intra-specific variation in the partial
mt sequences within T. malaysiensis was only 0.0–0.9%
[32]. Microheterogeneity of T. cati appears to depend on
geographical latitude and it remains to be determined if
this heterogeneity plays a role in the response to therapy
and potential immune protection.
Burden of disease by geographic region
Toxocariasis has been reported in many countries
worldwide, with most cases occurring in France,
Austria, India, Japan, Korea, China, USA, and Brazil
(Additional file 2: Table S1). A total of 823 ocular toxo-
cariasis (OT) cases have been reported, including 282
cases in Europe, 317 cases in Asia, five cases in
Australia, 218 cases in Latin America, and one docu-
mented case in Tunisia (Additional file 2: Table S1).
The highest number of OT cases has been reported in
Japan and Korea, France, Brazil and the USA. Only 99
neurotoxocariasis (NT) cases have been recorded
worldwide, of which 46 cases occurred in Europe, 32
cases in Asia, 20 cases in the Americas, and only one
case in South Africa. The largest numbers of NT cases
have been reported in Lebanon (17 cases), Sakha Re-
public in Russian Federation (20 cases) and the USA (8
cases). A total of 247 visceral larva migrans (VLM)
cases have been reported worldwide, with the largest
numbers reported in Spain (61 cases; 63% of European
97 cases), India (14; 29% of Asian 49 cases), Argentina
and Brazil (16; 16% and 76; 75% of cases in South
American 101 cases). Eating raw cows’ liver is the main
route for acquiring toxocariasis in Japan and Korea,
whereas stray dogs and cats spreading eggs in environ-
ment are the main source of infection for people in
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India and other South East Asian countries. In devel-
oped countries, including the USA, France and Austria,
patients are infected via contact with soil contaminated
with Toxocara eggs, for example in playgrounds, sand-
pits and gardens.
Several seroepidemiological features of human toxocar-
iasis are shown in Additional file 2: Table S2. Some risk
factors of toxocariasis, such as gender, age, household’s de-
sign and construction material, and the presence of do-
mestic animals, have been identified. However, current
knowledge of important epidemiological features of toxo-
cariasis, such as the global burden of the disease,
disability-adjusted life years, and populations at risk, are
still to be determined. Since many infections are asymp-
tomatic and thus can be misdiagnosed, the global burden
of toxocariasis is likely to have been underestimated [3].
The global prevalence of human toxocariasis can be influ-
enced by a number of potentially confounding variables
that can contribute to differences in the reported toxocar-
iasis prevalence [3, 33]. To improve consistency of the re-
sults obtained from prevalence surveys, future studies
should consider using standardized diagnostic criteria and
should be performed by trained clinicians who can apply a
standardized set of toxocariasis case definitions.
Sources of contamination, route of transmission and
reservoirs
Dogs and cats are the most important animal hosts for
toxocariasis, especially in developing countries where
most cats and dogs have access to public parks and play-
grounds, serving as the main source of soil contamin-
ation, and posing a huge risk of human exposure to
infective eggs (Additional file 2: Table S3). However, in
some developed countries, e.g. the UK, urban and rural
foxes are the primary source of eggs and infections to
humans. Although dogs under six weeks of age excrete
more eggs than dogs older than 1 year of age, their lack
of access to public areas and the removal of their faeces
resulted in ranking foxes as the biggest contributor to
eggs (Additional file 2: Table S3). Toxocara prevalence is
usually higher in cubs, but the prevalence can be high
even in adult foxes [34].
Environmental contamination with Toxocara eggs is
common in most countries, mainly in urban public
parks, with positive rates of soil samples obtained from
parks ranging from 17.4 to 60.3% in Brazil, 14.4 to 20.6%
in the USA, 13.0 to 87.1% in Europe, 30.3 to 54.5% in
Africa and 6.6 to 63.3% in Asia [3–44]. In some tem-
perate countries, such as Germany and England, al-
though a few cases of human toxocariasis have been
reported [39, 44], environmental contamination with
Toxocara eggs has been found to be high. The pres-
ence of embryonated Toxocara eggs attached to the
hair of dogs, cats and foxes, represent another route by
which humans can acquire infection from dogs or cats
[45–48]. Although the total numbers of eggs detected
on animal hair varies, puppies and stray animals had
higher egg numbers in their coat than others [47, 48].
Evidence suggests that only a handful of animal species
might function as paratenic hosts, within which no further
development occurs. Paratenic hosts can disseminate in-
fective stages of the parasite and/or aid these stages in
avoiding unfavourable conditions during absence of the
natural host [6]. These paratenic hosts (animals) include
the common shrew (Sorex araneus), Eurasian harvest
mouse (Sorex minutes), Eurasian water shrew (Neomys
fodiens), Mediterranean water shrew (Neomy sanomalus),
lesser white-toothed shrew (Crocidura suaveolens), com-
mon dormouse (Muscardinus avellanarius), house mouse
(Mus musculus), harvest mouse (Micromys minutus),
striped field mouse (Apodemus agrarius), yellow-necked
mouse (Apodemus flavicollis), wood mouse (Apodemus
silvaticus), Ural field mouse (Apodemus microps), brown
rat (Rattus norvegicus), bank vole (Clethrionomys glareo-
lus), common pine vole (Pitymys subterraneus), and com-
mon vole (Microtus arvalis) [49]. To date, a few studies
have identified the prevalence of infection in these ani-
mals. In Slovak Republic, 10 non-commensal rodents
from suburban locations were confirmed to have higher
seropositivity, with the highest seropositivity being found
in Apodemus agrarius (21%) [50]. In an urban area of
Switzerland, four species of non-commensal rodents had a
13.2% Toxocara seroprevalence [51].
Clinical presentation and associated disease syndromes
Toxocara infections are often associated with consider-
able variability in clinical presentation. Because T. canis
larvae migrate to various body organs, such as the liver,
heart, lungs, kidneys, brain, muscle and eyes, a broad
range of clinical symptoms can be developed (Table 1)
[7]. In general, human toxocariasis is categorized into
four clinical forms: VLM, OT, Covert or Common Toxo-
cariasis (CT), and NT, depending on which organs are
affected. The severity of disease is dependent on the
parasite burden, the duration of larval migration, and
age- and immune-mediated responses of the affected
individuals [7, 9, 15, 33, 52].
VLM
VLM is the consequence of a systemic migration of
Toxocara larvae through the tissue of human viscera. It
occurs in children aged 2–7 years and results from high
intensity or repeated infections by T. canis larvae. Infec-
tions in adult individuals have been reported in East
Asia (e.g. South Korea and Japan), through ingestion of
raw beef, lamb, chicken, or ostrich liver [53, 54]. The
liver is the most commonly affected organ in VLM, and
is associated with the formation of granulomatous
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lesions and hepatitis [55–57]. Less frequently, larvae
may invade other organs, such as heart, lungs, kidneys
and muscle, resulting in myocarditis, myalgia with eo-
sinophilic polymyositis, arthritis and nephritis [58–62].
Dermatological changes, such as rash, pruritus, eczema,
panniculitis, urticaria and vasculitis, have also been
detected in some VLM cases [63].
OT
Common pathologies observed in OT include posterior
pole and peripheral retinochoroiditis with granuloma, scler-
itis, chronic endophthalmitis and panuveitis [7, 8]. Other
abnormalities include vitreous opacities, yellowish-white
intraretinal lesions in the optic disc with papilledema, live
intraocular worm, papillitis, and a tractional retinal detach-
ment, and diffuse unilateral subacute neuroretinitis. The
level of visual impairment is dependent on the location of
the larvae, the extent of eosinophilia and the fibrotic granu-
lomatous response involved in the induction of distortion,
heterotopia and/or detachment of the macula [64, 65].
CT
In this form of toxocariasis, patients exhibit non-specific
symptoms, such as abdominal pain, fever, anorexia, nausea,
headache, vomiting, pharyngitis, pneumonia, cough, wheeze
and cervical lymphadenitis, which can be accompanied with
eosinophilia and positive Toxocara serology [4, 7].
NT
NT is caused by invasion of Toxocara larvae to the brain
and spinal cord, leading to cerebral lesions and neurological
damage, predominantly located in the cerebral and cerebel-
lar white matter, with occlusion of cerebral blood vessels
(Table 1). The associated clinical symptoms include myeli-
tis, encephalitis, mental confusion and/or meningitis. NT
can be influenced by many factors, such as host genetics,
the number of ingested ova and prior exposure [8, 66].
Diagnosis
Misdiagnosis due to the nonspecific clinical presentation,
may lead to prolonged morbidity and development of
Table 1 Characteristics of the different clinical forms of toxocariasis
Clinical syndromes Population Involved sites Associated symptoms
VLM Children aged 2–7 years Liver, heart, lungs, kidneys,
and muscle
Fever, respiratory symptoms (such as cough, wheeze, dyspnoea,
bronchospasm, asthma), hepatomegaly, abdominal pain, vomiting,
diarrhoea, anorexia, weight loss, fatigue, neurological manifestations,
and pallor [1, 52].
OT Children aged 5–10 years Eye Toxocara larval invasion of the peripheral retina and vitreous can
cause three major clinical types of OT syndrome over days to weeks:
diffuse nematode endophthalmitis, peripheral inflammatory mass
type and posterior pole granuloma type [104, 117–119]. Also, diffuse
unilateral subacute neuroretinitis (DUSN), bilateral distal symmetric
sensory neuropathy (DSN), and choroidal neovascular membrane
formation have been attributed to prolonged Toxocara infection
[1, 120, 121]. Predominantly unilaterally or uncommon bilateral ocular
involvement, characterized by visual impairment, strabismus,
leukocoria, solid retinal mass predominantly at the posterior pole,
vitreous mass or haze, retinal detachment, cataract, endophthalmitis,
papillitis, uveitis, as well asvisual loss, vitritis, papillitis and evanescent
outer retinal lesions leading to optic atrophy, retinal-artery narrowing
and diffuse-pigment epithelial degeneration [1, 122–125].
CT Children and adults No specific sites In adults: breathing difficulties, rash, pruritus, weakness, and abdominal
pain, elevated titers of anti-Toxocara antibodies, eosinophilia, and
elevated total IgE levels [126].
In children: pyrexia, headache, loss of appetite, nausea, emesis, lethargy,
behavior and sleep disorders, abdominal pain, pharyngitis, pneumonia,
cough, wheeze, itching, rash, limb pains, cervical lymphadenitis, pruritus,
rash, and hepatomegaly [52].
NT Children and adults Brain and spinal cord Headache, fever, photophobia, weakness, dorsalgia, confusion,
tiredness, visual impairment, epileptic seizures, neuropsychological
disturbances, dementia and depression [7, 127–129]. Motor impairment
can also be observed in clinical NT cases, such as ataxia, rigor, para-
or tetraparesis dysaesthesia, urinary retention, and faecal incontinence
[7, 107, 130, 131]. Rarely recognizable neurological signs of eosinophilic
meningitis, encephalitis, myelitis, cerebral vasculitis, epilepsy,
neuropsychologic deficits or combined pathological presentations,
which may be associated with repeated low dose infections, or
cerebral vasculitis under anthelmintic therapy, optic neuritis, other
cranial nerve involvement, and meningo-radiculitis [6, 7, 127, 132].
VLM Visceral larva migrans, OT Ocular toxocariasis, CT Covert or common toxocariasis, NT Neurotoxocariasis, DUSN Diffuse unilateral subacute neuroretinitis, DSN
Distal symmetric sensory neuropathy
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health complications. A high index of suspicion is there-
fore necessary to establish an early diagnosis and start ap-
propriate treatment. Also, diagnosis of toxocariasis should
rely on clinical, radiographic and laboratory evidence of
the disease [13, 14]. In general, diagnosis of toxocariasis is
based on history (e.g. individuals consumed raw or under-
cooked meat [7, 13]), clinical examination, direct micro-
scopic examination of tissues (eosinophilic granuloma
surrounding live or degenerated roundworm larvae), and
blood analysis (leukocytosis and eosinophilia). A range of
serological and molecular methods are also available
(Table 2) and can be used to confirm the diagnosis.
Direct microscopy
Demonstrating the presence of Toxocara larvae in tissue
biopsy, cerebrospinal fluid (CSF) or ocular fluids using
direct microscopy remains the “gold standard” for the
diagnosis of toxocariasis [13]. However, this method is
invasive, insensitive and time-consuming [14]. Also, it
can be difficult to distinguish between larvae of Toxo-
cara and those of other ascarids, especially when the
larvae are degenerated or when only parts of the larva
can be recovered from tissues [9, 67].
Serodiagnostics
Serological tests are used to support the clinical diagno-
sis of toxocariasis. Immunoelectrophoresis (IEP) has
shown an excellent specificity, but its low sensitivity has
limited its utility in clinical settings [13]. Enzyme-linked
immunosorbent assay (ELISA), based on excretory and
secretory antigens of the third stage larvae (L3) of T.
canis, is commonly used for diagnosis of human toxo-
cariasis [1]. A limitation of T. canis antigen testing is the
significant cross-reactivity with other helminths, such
as Ascaris lumbricoides, particularly in endemic areas
[13, 14]. Also, the level of serum IgG can remain ele-
vated for years, which precludes the discrimination
between active and persistent infections, especially in
patients with high infection intensity [13]. Despite the
potential false-positive reaction, these assays have clin-
ical significance that should not be ignored. Although a
positive test does not imply causation, a negative test
can help to rule out toxocariasis. Serological tests for
detecting T. canis antibodies may have less value in the
evaluation of disease progression in the CNS because
results of ELISA for T. canis antibodies can be positive
in serum, but negative in the CSF of NT patients [68].
Recombinant Toxocara antigens have been shown to
improve the sensitivity and specificity of serological
testing [14]. A combination of diagnostic tests is gener-
ally used in seroepidemiological studies (e.g. ELISA is
initially used as a fast and relatively inexpensive
method, followed by Western blotting to improve the
sensitivity and specificity) [13]. Specific detection of
total anti-Toxocara IgG antibodies and subclasses (e.g.
IgG1, IgG2, IgG3 and IgG4) are also possible [69]. Various
parasite antigens, semi-purified, and crude antigens from
T. canis larvae (TCLA), have been used to detect IgM,
IgG or IgG4 using ELISA tests with satisfactory sensitivity
and specificity [70, 71]. In addition, IgE- and IgM- based
ELISAs can be used to evaluate the effect of treatment by
monitoring the antibody titer post-treatment [70].
Molecular detection
Molecular techniques have high analytical specificity,
and shorter turnaround times than other diagnostics.
PCR-based assays using a variety of genetic markers (e.g.
ITS-1 and ITS-2 regions of rDNA) have been developed
and have enabled the identification and phylogenetic
analysis of T. canis, T. cati and other ascarids [72–74].
PCR-based testing has been utilized to identify T. canis
larvae collected from human biopsies in ocular larva
migrans (OT) and from CSF in NT [9, 75, 76]. PCR-
based assays, including quantitative real-time PCR
(qPCR), PCR-RFLP and PCR-RAPD have been used for
accurate identification and diagnosis of Toxocara eggs
isolated from faeces or soil (Table 2) [2]. The develop-
ment of loop-mediated isothermal amplification (LAMP)
of nucleic acid has provided a rapid and cheap approach
for assessing the contamination of soil with Toxocara
eggs [77, 78]. Molecular methods with improved per-
formance characteristics have the potential to advance
the diagnosis of toxocariasis.
Diagnostic imaging
A variety of imaging modalities have been used for the
detection of lesions caused by infection with Toxocara
larvae, such as magnetic resonance imaging (MRI),
computed tomography (CT), ultrasound, fundus photog-
raphy, fluorescein angiography, ophthalmic ultrasound
and optical coherence tomography (OCT) [79–85].
Imaging findings in OT
Fundus photography, fluorescein angiography, ophthal-
mic ultrasound and OCT can assist in the detection of
eye granulomas and in the differentiation of OT from
similar ocular conditions, such as retinoblastoma.
Routine fundus photography can reveal the location and
effects of focal granulomas in eyes with clear media, and
in monitoring changes related to disease progression or
in response to treatment [86]. Wide-field imaging may
aid in the management of patients with peripheral visual
involvement. Angiography is used to document the
effects of focal and diffuse inflammation on retinal vas-
culature. Ultrasound biomicroscopy (UBM) can be valu-
able in detecting the location and extent of vitreous
bands and/or traction affecting the anterior segment in-
cluding the ciliary body, pars plana and peripheral retina
Chen et al. Infectious Diseases of Poverty  (2018) 7:59 Page 5 of 13
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[85, 87]. High-penetration optical coherence tomography
(HP-OCT) is useful for examining intraretinal lesions,
noninvasively. HP-OCT provides clear and continuous
scanning from the retina to the choroid [82], compared
with conventional OCT.
Imaging findings in NT
In NT patients, MRI and CT can be used to detect
lesions caused by migrating Toxocara larvae in neural
tissues. The diagnostic features of NT on MRI include
single or multiple, subcortical, cortical or white matter
hyperintense lesions on T2-weighted and FLAIR images,
and hypointense on T1-weighted images [68, 88]. How-
ever, these imaging features are only suggestive, not
specific to NT. Therefore, serologic studies of blood and
CSF, eosinophilia in the serum or CSF, and clinical and
radiological improvement after anthelmintic treatment
are necessary to establish the diagnosis.
Imaging findings in VLM
VLM lesions appeared on the ultrasound (US) scan as
multiple ill-defined, non-spherical hypoechoic lesions
[89]. Contrast-enhanced computed tomography of the
liver revealed VLM as fluid-attenuating conglomerate
lesions [89, 90]. On MRI scan hepatic lesions caused by
Toxocara L3 larvae migration appeared hypointense on
T1-weighted (T1W) images and hyperintense on T2-
weighted (T2W) images [89]. VLM lesions exhibited re-
duced signal intensity on superparamagnetic iron oxide-
enhanced T2-weighted MRI images [91]. Based on the
radiographic features, fine needle aspiration cytology
through the hepatic lesion can be used to characterize
the lesion’s content. The presence of mixed inflammatory
cells predominantly eosinophils along with Charcot-
Leydon crystals in a necrotic background can suggest
VLM [90].
Differential diagnosis
Despite growing efforts to develop a range of diagnostic
methods for detection of human toxocariasis, accurate
diagnosis remains a challenge. To improve the manage-
ment of toxocariasis, we must distinguish this disease
from similar conditions. Hence, NT should be differenti-
ated from neural larva migrans (NLM) caused by the
nematode Baylisascaris procyonis. Also, in clinical cases of
meningeal, cerebral, or spinal cord disease with hypereosi-
nophilia of unknown origin and cerebral granulomatous,
differential diagnosis of NT should not be overlooked. Dif-
ferential diagnosis of OT should consider excluding prolif-
erative and neoplastic pathologies (retinoblastoma), and
other coexisting parasitic zoonoses (e.g. angiostrongyliasis,
toxoplasmosis, cysticercosis, gnathostomiasis, thelaziasis,
trichinosis), bacterial infections (e.g. Lyme borreliosis) or
viral infections (e.g. cytomegaly). Future research is
required to develop better diagnostic methods for detect-
ing the causative parasite, so as to best direct appropriate
resources.
Treatment
The mainstay of toxocariasis therapies includes anthel-
mintics (e.g. albendazole [ABZ], mebendazole [MBZ]
and thiabendazole) and anti-inflammatory drugs [14].
These drugs are used to achieve a clinical resolution or
to reduce the damage caused by larval migration to vari-
ous organs, particularly the brain and eyes [92–94]. ABZ
at 400 mg twice a day for five days is the first choice for
treatment of VLM patients [1, 13], but MBZ has been
indicated as the second therapeutic option for VLM, due
to its lower absorption rate outside the gastrointestinal
tract compared to ABZ [11, 52]. Other anthelmintic
drugs such as diethylcarbamazine (DEC) and ivermectin
have been explored to treat VLM, but ivermectin has
uncertain efficacy [11, 52]. In cases with cardiac in-
volvement, regimens involving 800 mg/day for two
weeks, 50 mg/(kg·day) for 28 days, 600 mg/day for
14 days, or 1000 mg/day for four weeks have been
used [58]. Corticosteroids have been used in cases of
pulmonary toxocariasis and toxocariasis-associated
cardiac diseases [95, 96].
Despite the lack of an optimal treatment for OT,
some patients can be treated successfully with anthel-
mintic drugs or surgically (Table 3), depending on the
severity of intraocular inflammation and retinal comor-
bidities [97–99]. Current standard treatment for OT
with active intraocular inflammation includes systemic
corticosteroid in combination with ABZ [100]. Periocu-
lar or systemic steroids can limit the inflammation, fi-
brosis, or cicatrization in eyes with active vitritis.
Surgery is advised for treatment of structural complica-
tions [101–103]. Cryotherapy can be used to treat
granulomas, with the administration of steroids following
the procedure [104].
Combinations of corticosteroids with DEC, MBZ,
orthiabendazole have been used for the treatment of NT
[7]. Although NT may resolve from treatment using
ABZ, MBZ, thiabendazole and DEC, ABZ used for at
least three weeks, which often needed to be repeated is
the preferable choice because it can penetrate the CSF
with a minimal toxicity [105, 106]. Corticosteroids can
be used for reducing inflammation and controlling
hypersensitivity reactions caused by degenerated larvae
following the treatment of NT [107]. Encouraging re-
sults have been reported recently where a long-term ad-
ministration of ABZ (10–15 mg/[kg·day]) for four weeks
or eight weeks resulted in recovery rate of 78.9 and 81.
3%, respectively [11, 108]. Monitoring of side effects
post-treatment is recommended especially in patients
who might be at a high risk of treatment complications,
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including people with allergies, pregnant or lactating
women, children weighing less than 15 kg, older pa-
tients, and those concurrently taking other medicines.
Prevention
The rapid increase in the number of dogs and cats, espe-
cially uncontrolled feral and stray populations and their
close proximity to humans, has increased the risk of
human infection with Toxocara [109]. The lack of an ef-
fective method to kill Toxocara eggs makes it impossible
to eradicate this parasite from the environment [110].
Therefore, strategies for preventing infection should
include measures to prevent initial contamination of the
environment [2]. Various measures can be imple-
mented to interrupt the transmission of Toxocara eggs
from animals to humans. These involve de-worming
household pets frequently and from a young age. Par-
ticular attention and prophylactic anthelmintics should
be given to puppies, kittens, or pregnant bitches, which
are most likely to transmit the disease. Owners should
also safely collect and hygienically dispose of pet
faeces, before the eggs become infective. The World
Health Organization (WHO) published useful recom-
mendations for disposal of faeces of infected dogs and
cats in order to break the dog-soil-human transmission
cycle of toxocariasis [111].
Table 3 Treatment regimens for human toxocariasis
Clinical forms Alternatives Regimens Remarks Therapeutic efficacy
VLM
Albendazole (ABZ) [92, 93, 140] First choice 400 mg orally twice a
day for 5 days
Mild side effects (e.g. dizziness,
nausea, abdominal pain) were
observed in some patients
The cure rates (45–70%)
Mebendazole (MBZ) [52, 95] Second choice 100–200 mg orally
twice a day for 5 days
Mild side effects similar to
adverse effects caused by ABZ
The cure rates (45–70%)
Diethylcarbamazine (DEC) [52, 93] Alternative choice 40 mg/kg per day for
6 months
Hypersensitivity (e.g. itching,
urticaria and edema)
Reduced clinical signs in
70% of patients
Sodium lauryl sulfate containing
chitosan-encapsulated ABZ
(ABZ/CH); polyethylene glycol
(PEG)-conjugated (‘pegylated’)
form of ABZ (ABZ/PEG); liposome-
encapsulated ABZ stabilized with
PEG (ABZ/PEG-LE); phytochemical
compounds (compound 17, or
C17) [100, 141–144]
Other treatments Only used in mice models To increase efficacy, co-
administration of a fatty
meal with the drugs are
recommended for treatment
of VLM; liposomal formulations
can overcome low drug
absorptivity in mice [97, 145]
Uncertain
OT
Corticosteroid in combination
with ABZ [98]
First choice 400 mg of ABZ orally
twice a day for 5 days
Prevents scarring, vitreous
opacification, membrane
formation and vision loss;
corticosteroid can increase
blood level of ABZ
Uncertain
Surgery [101, 102] Alternative choice Vitreoretinal surgery
treatment e.g. pars plana
vitrectomy (PPV), laser
photocoagulation, and
cryotherapy
Indicated in cases of
retinal detachment, epiretinal
membrane, persistent vitreous
opacity, and cataracts.
NR
ABZ [99, 101] Other treatments 200 mg twice a day for
one month and 400 or
800 mg twice a day for
2 weeks
Reversible side effects, such
as hepatotoxicity, leucopenia,
and alopecia; should be avoided
during pregnancy
Uncertain
MBZ [99, 101] Other treatments 20 to 25 mg/kg/day for
3 weeks
The optimal duration of
treatment is unknown
Uncertain
Thiabendazole [99, 101] Other treatments 25 to 50 mg/kg/day for
5–7 days
The optimal duration of
treatment is unknown
Uncertain
CT
ABZ [105] First choice 200 mg twice a day for
one month and 400 or
800 mg twice a day for
2 weeks
ABZ is better tolerated
than thiabendazole
Uncertain
ABZ Albendazole, MBZ Mebendazole, DEC Diethylcarbamazine, NR Not relevant, OT Ocular toxocariasis, CT Covert or common toxocariasis, VLM Visceral
larva migrans
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Prevention of human infections can also be achieved
by washing hands after touching or playing with pets, or
following exposure to potentially contaminated sites.
Parents should educate children about basic personal hy-
gienic precautions, such as the need for frequent hand
washing and the dangers of eating dirt. Children’s play
areas should be regularly cleaned and pets kept out of
outdoor play areas (e.g. sandboxes) by covering or
fencing them off. In addition to measures mentioned
above, other interventions have been tested in animal
models and may provide alternatives for the prevention
of toxocariasis. For example, probiotics (Enterococcus
faecalis CECT 7121 and Saccharomyces boulardii) and
DNA-based vaccines (pcDNA3/CpG and pcDNA3/IL-
12) have been tested in animal models. E. faecalis CECT
7121 and S. boulardii significantly reduced the burden
of larvae in the liver, lungs and brain significantly
[112–114]. DNA vaccination with pcDNA3/CpG and
pcDNA3/IL-12 reduced eosinophilia and airway
hyper-responsiveness, respectively [115]. Solid lipid
nanoparticles of ABZ has been suggested as a promis-
ing formulation for the treatment of T. canis infection
in mice [116].
Conclusions
Despite extraordinary progress during the past two
decades, toxocariasis continues to pose a significant
challenge to the public health. This challenge includes
a need for continued surveillance to better define the
burden of toxocariasis, which requires timely, efficient
diagnosis; a need to develop and deploy new drugs and
vaccines to combat clinical disease; and a need for on-
going research not only in developing appropriately-tar-
geted prevention strategies, but also in understanding
the infection biology of Toxocara spp. and human re-
sponses to them. Future directions in basic and
applied research likely will include: (i) molecular
characterization of Toxocara isolates from clinical and
environmental sources to identify novel biomarkers
for diagnosis and epidemiological surveys; (ii) better
understanding of humoral, innate, and cell-mediated
immunity to Toxocara infection for development of
prophylactic or therapeutic vaccines; and (iii) estab-
lishment of a database that includes behavioural,
climatic, demographic, ecological, and socioeconomic
factors, crucial data for prediction of infection risk,
and for improving the effectiveness of public health
interventions by focusing on populations with the
highest probability of benefit. Successful realization of
these research priorities can advance the understand-
ing of toxocariasis and promote the development of
new interventions to prevent Toxocara infection and
minimize its impact on society.
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